|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:aims_to
|
Enhance patient outcomes
Reduce healthcare costs
Improve treatment options
|
|
gptkbp:benefits
|
Patent expirations
|
|
gptkbp:challenges
|
Regulatory hurdles
Market acceptance
Competition from originator drugs
|
|
gptkbp:collaborates_with
|
Research institutions
Healthcare providers
|
|
gptkbp:competes_with
|
Other biosimilar manufacturers
|
|
gptkbp:contributes_to
|
Market competition
Patient access
|
|
gptkbp:developed_by
|
gptkb:Merck_Research_Laboratories
Chronic diseases
|
|
gptkbp:focus
|
Biopharmaceuticals
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Merck Biosimilars
|
|
gptkbp:includes
|
gptkb:Biosimilar_to_Adalimumab
gptkb:Biosimilar_to_Infliximab
gptkb:Biosimilar_to_Rituximab
gptkb:Biosimilar_to_Trastuzumab
|
|
gptkbp:is_aligned_with
|
Global health initiatives
Sustainability goals
|
|
gptkbp:is_available_in
|
Pharmacies
|
|
gptkbp:is_distributed_by
|
Pharmaceutical wholesalers
|
|
gptkbp:is_evaluated_by
|
Cost-effectiveness
Clinical guidelines
Safety and efficacy
Health technology assessments
|
|
gptkbp:is_influenced_by
|
Healthcare policies
Insurance coverage
|
|
gptkbp:is_informed_by
|
Market research
Patient feedback
|
|
gptkbp:is_part_of
|
Biopharmaceutical industry
Merck's strategy
|
|
gptkbp:is_prominent_in
|
Emerging markets
Developed markets
|
|
gptkbp:is_promoted_by
|
Healthcare professionals
Patient advocacy groups
|
|
gptkbp:is_promoted_through
|
gptkb:Marketing_campaigns
|
|
gptkbp:is_recognized_for
|
Quality standards
Innovation in biopharmaceuticals
|
|
gptkbp:is_subject_to
|
Reimbursement policies
Pricing regulations
|
|
gptkbp:is_supported_by
|
gptkb:Scientific_research
Clinical evidence
|
|
gptkbp:is_targeted_at
|
Regulatory agencies
Market analysts
|
|
gptkbp:is_used_for
|
Treatment of diseases
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:United_States
|
|
gptkbp:part_of
|
Merck's portfolio
|
|
gptkbp:produced_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:requires
|
Clinical trials
Regulatory submissions
|
|
gptkbp:research_and_development
|
Ongoing
|
|
gptkbp:target_market
|
gptkb:Oncology
Autoimmune diseases
Inflammatory diseases
|
|
gptkbp:type_of
|
Generic drug
|
|
gptkbp:bfsParent
|
gptkb:Merck_KGa_A_Consumer_Health
|
|
gptkbp:bfsLayer
|
5
|